New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations of cost, inconvenience, toxic effects, efficacy of retreatment, and lack of survival benefit should focus future clinical research on more-effective induction strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Flowers, C. et al. Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a8100 (2010).
Salles, G. et al. Rituximab manitenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42–51 (2011).
Martinelli, G. et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J. Clin. Oncol. 28, 4480–4484 (2010).
Ardeshna, K. M. et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis [abstract]. Blood 116, a6 (2010).
Hochster, H. et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progession-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J. Clin. Oncol. 27, 1607–1614 (2009).
van Oers, M. H. et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J. Clin. Oncol. 28, 2853–2858 (2010).
Hainsworth, J. D. et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23, 1088–1095 (2005).
van Oers, M. H. et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108, 3295–3301 (2006).
Forstpointner, R. et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108, 4003–4008 (2006).
Gisselbrecht, C. et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study [abstract 8509]. J. Clin. Oncol. 27, 436s (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Cheson, B. Rituximab for follicular lymphoma: maintaining an open mind. Nat Rev Clin Oncol 8, 257–258 (2011). https://doi.org/10.1038/nrclinonc.2011.35
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.35
